AI-powered radiation reduction solution gains FDA clearance

Sanford, Florida-based Omega Medical Imaging announced that its new FluoroShield radiation reduction system has received FDA approval.

The AI-powered imaging solution reduces patients’ exposure to radiation and produces high-quality blended images to be used during interventional procedures. It can also be positioned manually, giving users more freedom than normal as they care for patients.

According to Omega Medical Imaging, this is the first solution of its kind to hit the market.

“FluoroShield is the only system in the world that provides an actual reduction in dose,” Brian Fleming, president of Omega Medical Imaging, said in a prepared statement. “The impact of this groundbreaking solution for patients and healthcare providers is substantial. I am very grateful to be a part of a team that pushes the envelope in the development of safer healthcare solutions.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.